prof. dr. H.W. (Hans) Nijman

Hans W. Nijman, gynaecologic oncologist at the University Medical Center in Groningen (since 2003), was appointed head of the Department of Obstetrics and Gynecology on March 1, 2015.  Hans was trained in Amsterdam (VUMC and St Lucas- Andreas Hospital) and Utrecht (Diakonessenhuis) as a resident in Obstetrics & Gynaecology (1995 - 2000). Prior to that he completed his PhD in immunology in 1995 , and was registrated as an immunologist. After his training in ObGyn he did his fellowship in gynecologic oncology (2001- 2002), in Toronto, Canada. In 2008, he was appointed professor of gynecologic oncology and immunotherapy at the University of Groningen, Netherlands. His research group conducts translational and early clinical research in the field of tumor immunology. He is also, among other things, a driving force behind the formation of oncology networks to achieve accurate and sustainable care for every patient with cancer.

Additional activities:
Received compensation (paid to the institute) for advisory roles for Merck Sharp & Dohme, grants from the Dutch Cancer Society (KWF), the European Research Council (ERC), Health Holland (HH), Mendus, BioNovion, Aduro Biotech, Vicinivax and Genmab (all paid to the institute), non-financial support from BioNTech and Merck Sharp & Dohme, and is Director Clinical Research and stockholder in Vicinivax and stockholder in Sairopa, the latter in part relating to a patent for Antibodies targeting CD103